Eli Lilly ROE 2010-2022 | LLY

Current and historical return on equity (ROE) values for Eli Lilly (LLY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Eli Lilly ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $5.69B $8.66B 64.63%
2022-03-31 $6.13B $9.46B 73.77%
2021-12-31 $5.58B $9.16B 72.31%
2021-09-30 $5.97B $7.95B 86.73%
2021-06-30 $6.07B $6.66B 98.76%
2021-03-31 $6.09B $7.10B 109.81%
2020-12-31 $6.19B $5.83B 135.46%
2020-09-30 $5.57B $5.00B 147.01%
2020-06-30 $5.62B $4.27B 164.90%
2020-03-31 $5.53B $3.20B 181.22%
2019-12-31 $8.32B $2.70B 287.28%
2019-09-30 $7.95B $3.46B 160.62%
2019-06-30 $7.84B $2.86B 102.93%
2019-03-31 $6.26B $2.57B 63.77%
2018-12-31 $3.23B $10.91B 25.22%
2018-09-30 $0.45B $14.15B 3.46%
2018-06-30 $-0.14B $11.62B -1.09%
2018-03-31 $1.12B $14.59B 8.12%
2017-12-31 $-0.20B $11.67B -1.49%
2017-09-30 $2.23B $14.96B 15.53%
2017-06-30 $2.45B $14.17B 16.88%
2017-03-31 $2.19B $14.10B 14.96%
2016-12-31 $2.74B $14.08B 18.44%
2016-09-30 $2.44B $15.62B 16.32%
2016-06-30 $2.47B $14.66B 16.57%
2016-03-31 $2.32B $15.03B 15.57%
2015-12-31 $2.41B $14.59B 16.20%
2015-09-30 $2.36B $15.24B 15.66%
2015-06-30 $2.06B $14.71B 13.14%
2015-03-31 $2.19B $14.95B 13.29%
2014-12-31 $2.39B $15.39B 13.78%
2014-09-30 $2.69B $17.68B 15.01%
2014-06-30 $3.39B $18.00B 19.14%
2014-03-31 $3.86B $18.35B 22.69%
2013-12-31 $4.68B $17.64B 28.95%
2013-09-30 $4.78B $16.90B 30.93%
2013-06-30 $4.91B $15.24B 32.17%
2013-03-31 $4.63B $14.96B 30.79%
2012-12-31 $4.09B $14.77B 27.28%
2012-09-30 $4.12B $16.06B 28.06%
2012-06-30 $4.03B $14.31B 27.92%
2012-03-31 $4.30B $14.82B 29.83%
2011-12-31 $4.35B $13.54B 30.61%
2011-09-30 $4.66B $15.06B 33.47%
2011-06-30 $4.73B $14.28B 35.65%
2011-03-31 $4.88B $13.93B 39.83%
2010-12-31 $5.07B $12.41B 44.56%
2010-09-30 $4.82B $12.41B 45.18%
2010-06-30 $4.45B $10.24B 44.40%
2010-03-31 $4.26B $10.46B 44.36%
2009-12-31 $4.33B $9.53B 48.48%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.922B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22